APA (7th ed.) Citation

D, G., MN, R., M, I., AR, H., L, R., DM, F., . . . RC, R. (2025). Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: A randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis. The Lancet. Microbe, 6(12), 101211. https://doi.org/10.1016/j.lanmic.2025.101211

Chicago Style (17th ed.) Citation

D, Gbesemete, et al. "Efficacy, Immunogenicity, and Safety of the Live Attenuated Nasal Pertussis Vaccine, BPZE1, in the UK: A Randomised, Placebo-controlled, Phase 2b Trial Using a Controlled Human Infection Model with Virulent Bordetella Pertussis." The Lancet. Microbe 6, no. 12 (2025): 101211. https://doi.org/10.1016/j.lanmic.2025.101211.

MLA (9th ed.) Citation

D, Gbesemete, et al. "Efficacy, Immunogenicity, and Safety of the Live Attenuated Nasal Pertussis Vaccine, BPZE1, in the UK: A Randomised, Placebo-controlled, Phase 2b Trial Using a Controlled Human Infection Model with Virulent Bordetella Pertussis." The Lancet. Microbe, vol. 6, no. 12, 2025, p. 101211, https://doi.org/10.1016/j.lanmic.2025.101211.